Company News-宜明昂科英文

2026-01-14

Palverafusp α (IMM2510) Receives NMPA Approval for Phase II/III Clinical Trial in Endometrial Cancer

Shanghai, China, January 14, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the Investigational New Drug (IND) application for a Phase II

2026-01-12

ImmuneOnco Biopharmaceuticals' timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis

Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp

2026-01-09

ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™

Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t

2026-01-07

ImmuneOnco Announces IND Acceptance for IMM0306 (Amouravfop Alfa) Monotherapy in Primary Membranous Nephropathy, Advancing Comprehensive Autoimmune Pipeline

NMPA has officially accepted the IND for IMM0306 monotherapy in Primary Membranous Nephropathy (PMN).

2026-01-06

ImmuneOnco Regains Global Rights to IMM2510/AXN-2510 and IMM27M/AXN-27M Following Axion Bio's Discontinuation

SHANGHAI, January 6, 2026 -- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc.,